{"id":43462,"date":"2025-10-15T17:25:21","date_gmt":"2025-10-15T09:25:21","guid":{"rendered":"https:\/\/flcube.com\/?p=43462"},"modified":"2025-10-15T17:25:22","modified_gmt":"2025-10-15T09:25:22","slug":"pfizer-reports-positive-phase-3-her2climb%e2%80%9105-results-for-tukysa-tucatinib-in-first%e2%80%91line-her2-mbc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=43462","title":{"rendered":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE: PFE<\/a>) today announced compelling topline results from the <strong>Phase\u202f3 HER2CLIMB\u201105<\/strong> trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor <strong>TUKYSA<\/strong> (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with <strong>HER2\u2011positive metastatic breast cancer (MBC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-findings\">Key Findings<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>TUKYSA\u202f+\u202fTrastuzumab\u202f+\u202fPertuzumab<\/th><th>Placebo\u202f+\u202fTrastuzumab\u202f+\u202fPertuzumab<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression\u2011Free Survival (PFS)<\/td><td>PFS<\/td><\/tr><tr><td><strong>Median PFS<\/strong><\/td><td>19.9\u202fmonths<\/td><td>14.7\u202fmonths<\/td><\/tr><tr><td><strong>Hazard Ratio<\/strong><\/td><td>0.70 (95%\u202fCI 0.58\u20110.84)<\/td><td>\u2013<\/td><\/tr><tr><td><strong>Statistical Significance<\/strong><\/td><td>p\u202f&lt;\u202f0.001<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Statistically significant<\/strong> improvement in investigator\u2011assessed PFS (HR\u202f0.70,\u202fp\u202f&lt;\u202f0.001).<\/li>\n\n\n\n<li><strong>Clinically meaningful<\/strong> 5\u2011month PFS advantage in the TUKYSA arm.<\/li>\n\n\n\n<li><strong>Safety profile<\/strong> consistent with known TUKYSA, trastuzumab, and pertuzumab exposure; most common adverse events were diarrhea, nausea, and fatigue.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-trial-design\">Trial Design<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Population<\/strong>: Adults with HER2\u2011positive MBC, treatment\u2011na\u00efve for metastatic disease.<\/li>\n\n\n\n<li><strong>Intervention<\/strong>: TUKYSA (oral 300\u202fmg\u202fq.d.) plus trastuzumab\u202f+\u202fpertuzumab versus placebo plus trastuzumab\u202f+\u202fpertuzumab.<\/li>\n\n\n\n<li><strong>Randomization<\/strong>: 1:1, stratified by visceral disease status.<\/li>\n\n\n\n<li><strong>Primary Endpoint<\/strong>: Investigator\u2011assessed PFS per RECIST\u202fv1.1.<\/li>\n\n\n\n<li><strong>Secondary Endpoints<\/strong>: Overall survival, objective response rate, duration of response, safety, and patient\u2011reported outcomes.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-implications-for-clinical-practice\">Implications for Clinical Practice<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011line evidence<\/strong> supporting TUKYSA as part of a dual\u2011HER2 blockade regimen.<\/li>\n\n\n\n<li><strong>Potential to improve outcomes<\/strong> for patients with limited first\u2011line options, including those with brain metastases.<\/li>\n\n\n\n<li><strong>Safety profile<\/strong> reinforces TUKYSA\u2019s established tolerability in combination settings.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-forward-looking-statements\">Forward\u2011Looking Statements<\/h3>\n\n\n\n<p>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating&#8230;<\/p>\n","protected":false},"author":1,"featured_media":43463,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[17,863,309,33],"class_list":["post-43462","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-clinical-trial-results","tag-nyse-pfe","tag-pfizer","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with HER2\u2011positive metastatic breast cancer (MBC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=43462\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with HER2\u2011positive metastatic breast cancer (MBC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=43462\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-15T09:25:21+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-15T09:25:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC\",\"datePublished\":\"2025-10-15T09:25:21+00:00\",\"dateModified\":\"2025-10-15T09:25:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462\"},\"wordCount\":246,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1515.webp\",\"keywords\":[\"Clinical trial results\",\"NYSE: PFE\",\"Pfizer\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43462#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=43462\",\"name\":\"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1515.webp\",\"datePublished\":\"2025-10-15T09:25:21+00:00\",\"dateModified\":\"2025-10-15T09:25:22+00:00\",\"description\":\"Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with HER2\u2011positive metastatic breast cancer (MBC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=43462\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1515.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/1515.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=43462#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with HER2\u2011positive metastatic breast cancer (MBC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=43462","og_locale":"en_US","og_type":"article","og_title":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC","og_description":"Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with HER2\u2011positive metastatic breast cancer (MBC).","og_url":"https:\/\/flcube.com\/?p=43462","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-15T09:25:21+00:00","article_modified_time":"2025-10-15T09:25:22+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=43462#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=43462"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC","datePublished":"2025-10-15T09:25:21+00:00","dateModified":"2025-10-15T09:25:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=43462"},"wordCount":246,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=43462#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp","keywords":["Clinical trial results","NYSE: PFE","Pfizer","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=43462#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=43462","url":"https:\/\/flcube.com\/?p=43462","name":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=43462#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=43462#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp","datePublished":"2025-10-15T09:25:21+00:00","dateModified":"2025-10-15T09:25:22+00:00","description":"Pfizer Inc. (NYSE: PFE) today announced compelling topline results from the Phase\u202f3 HER2CLIMB\u201105 trial, evaluating the oral HER2 tyrosine\u2011kinase inhibitor TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as first\u2011line therapy for patients with HER2\u2011positive metastatic breast cancer (MBC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=43462#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=43462"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=43462#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp","width":1080,"height":608,"caption":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=43462#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Reports Positive Phase\u202f3 HER2CLIMB\u201105 Results for TUKYSA (Tucatinib) in First\u2011Line HER2+ MBC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/1515.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43462","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43462"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43462\/revisions"}],"predecessor-version":[{"id":43464,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/43462\/revisions\/43464"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/43463"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43462"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43462"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43462"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}